Cognition Therapeutics, Inc.
CGTX · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | 0.04 | 0.03 | -0.01 |
| FCF Yield | -28.50% | -37.96% | -25.74% | -36.17% |
| EV / EBITDA | -0.67 | -0.74 | -1.08 | 0.25 |
| Quality | ||||
| ROIC | -187.47% | -106.74% | -54.81% | -94.84% |
| Gross Margin | 0.00% | 0.00% | -28.40% | 0.00% |
| Cash Conversion Ratio | 1.15 | 0.84 | 1.16 | 1.07 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 43.07% | -17.82% | -22.36% | -14.18% |
| Safety | ||||
| Net Debt / EBITDA | 0.74 | 1.15 | 3.12 | 2.17 |
| Interest Coverage | -4,659.33 | -2,755.00 | -2,144.60 | -4,821.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,137.54 | -3,642.00 | -1,547.97 | -2,436.43 |